Key Inclusion Criteria:

          1. Subjects with confirmed diagnosis of recurrent or metastatic breast cancer based on
             histopathology examination

          2. Subjects with diagnosis of HER2-negative breast cancer that was confirmed by IHC or in
             situ hybridization (ISH) assessment of tumor samples

          3. Subjects who have received up to 3 lines of therapy for advanced disease, without
             prior exposure to taxane in the advanced stage setting

          4. Subjects who have a performance status of ≤2 on the Eastern Cooperative Oncology Group
             (ECOG) scale.

          5. Subjects who have measurable disease according to the Response Evaluation Criteria in
             Solid Tumors Version 1.1 (RECIST version 1.1).

        Key Exclusion Criteria:

          1. Subjects who have received prior taxane therapy in the metastatic setting

          2. Subjects whose adjuvant or neoadjuvant treatment for early stage breast cancer was
             completed within 6 months prior to entry into the study.

          3. Subjects with neuropathy grade ≥2 based on CTCAE v4.03 at the time of study entry

          4. Subjects with symptomatic, untreated metastases to the central nervous system (CNS) at
             the time of screening.

          5. Subjects who have received any investigational drugs or devices within 4 weeks before
             the first day of study treatment (C1D1).